U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H24N2O2
Molecular Weight 264.3633
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRACAINE

SMILES

CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C

InChI

InChIKey=GKCBAIGFKIBETG-UHFFFAOYSA-N
InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C15H24N2O2
Molecular Weight 264.3633
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tetracaine (INN, also known as amethocaine; trade name Pontocaine. Ametop and Dicaine) is a potent local anesthetic of the ester group. It is mainly used topically in ophthalmology and as an antipruritic, and it has been used in spinal anesthesia. Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. In biomedical research, tetracaine is used to alter the function of calcium release channels (ryanodine receptors) that control the release of calcium from intracellular stores. Tetracaine is an allosteric blocker of channel function. At low concentrations, tetracaine causes an initial inhibition of spontaneous calcium release events, while at high concentrations, tetracaine blocks release completely.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TETRACAINE HYDROCHLORIDE

Cmax

ValueDoseCo-administeredAnalytePopulation
0.24 ng/mL
18 mg single, nasal
TETRACAINE plasma
Homo sapiens
1.15 ng/mL
36 mg single, nasal
TETRACAINE plasma
Homo sapiens
886 ng/mL
36 mg single, nasal
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
492 ng/mL
18 mg single, nasal
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1773 ng × h/mL
36 mg single, nasal
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
862 ng × h/mL
18 mg single, nasal
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.01 h
36 mg single, nasal
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens
1 h
18 mg single, nasal
4-(BUTYLAMINO)BENZOIC ACID plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
One drop topically in the eye(s)
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
0619F35CGV
Record Status Validated (UNII)
Record Version